Novo Nordisk (Brazil) Performance
| N1VO34 Stock | BRL 83.70 1.45 1.76% |
The company secures a Beta (Market Risk) of 0.0961, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Novo Nordisk's returns are expected to increase less than the market. However, during the bear market, the loss of holding Novo Nordisk is expected to be smaller as well. At this point, Novo Nordisk AS has a negative expected return of -0.15%. Please make sure to verify Novo Nordisk's potential upside, kurtosis, daily balance of power, as well as the relationship between the skewness and accumulation distribution , to decide if Novo Nordisk AS performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Novo Nordisk AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
| Begin Period Cash Flow | 12.2 B | |
| Total Cashflows From Investing Activities | -31.6 B |
Novo |
Novo Nordisk Relative Risk vs. Return Landscape
If you would invest 9,353 in Novo Nordisk AS on September 13, 2024 and sell it today you would lose (983.00) from holding Novo Nordisk AS or give up 10.51% of portfolio value over 90 days. Novo Nordisk AS is generating negative expected returns and assumes 2.3045% volatility on return distribution over the 90 days horizon. Simply put, 20% of stocks are less volatile than Novo, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Novo Nordisk Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Novo Nordisk's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Novo Nordisk AS, and traders can use it to determine the average amount a Novo Nordisk's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0662
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | N1VO34 |
Estimated Market Risk
| 2.3 actual daily | 20 80% of assets are more volatile |
Expected Return
| -0.15 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Novo Nordisk is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Novo Nordisk by adding Novo Nordisk to a well-diversified portfolio.
Novo Nordisk Fundamentals Growth
Novo Stock prices reflect investors' perceptions of the future prospects and financial health of Novo Nordisk, and Novo Nordisk fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Novo Stock performance.
| Return On Equity | 0.72 | |||
| Return On Asset | 0.22 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.43 % | |||
| Current Valuation | 1.59 T | |||
| Shares Outstanding | 2.25 B | |||
| Price To Book | 3.46 X | |||
| Price To Sales | 9.46 X | |||
| Revenue | 140.8 B | |||
| EBITDA | 65.39 B | |||
| Total Debt | 9.65 B | |||
| Book Value Per Share | 37.10 X | |||
| Cash Flow From Operations | 55 B | |||
| Earnings Per Share | 18.22 X | |||
| Total Asset | 194.51 B | |||
About Novo Nordisk Performance
By analyzing Novo Nordisk's fundamental ratios, stakeholders can gain valuable insights into Novo Nordisk's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Novo Nordisk has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Novo Nordisk has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about Novo Nordisk AS performance evaluation
Checking the ongoing alerts about Novo Nordisk for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Novo Nordisk AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Novo Nordisk AS generated a negative expected return over the last 90 days |
- Analyzing Novo Nordisk's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Novo Nordisk's stock is overvalued or undervalued compared to its peers.
- Examining Novo Nordisk's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Novo Nordisk's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Novo Nordisk's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Novo Nordisk's stock. These opinions can provide insight into Novo Nordisk's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Novo Stock analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |